News/ News/ Oncology Merck gets a leg-up for Keytruda in first-line kidney cancer Phil Taylor Bristol-Myers Squibb, Cabometyx, Eisai, Exelixis, immuno-oncology, Inlyta, Keytruda, Lenvima, Merck & Co, Oncology, Opdivo, Pfizer, renal cell carcinoma, Sutent, Yervoy 0 Comment New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the Share X Merck gets a leg-up for Keytruda in first-line kidney cancer https://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/